JPRN-UMIN000013185已完成2 期
Randomized phase II study of dose schedule of TS-1 for resected Colorectal Cancer - Study of Alternate-day administrations of TS-1 for resected Colorectal Cancer
Clinical Study Group of Osaka (CSGO), Colorectal Cancer Treatment Group0 个研究点目标入组 170 人开始时间: 2014年2月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active double cancer 2)Synchronous or metachronous malignancy other than carcinoma in situ. 3)Severe postoperative complications. 4)Severe complication. 5)Severe diarrhea. 6)Severe infectious disease. 7)Medical history of severe anaphylaxis or allergia to any drug. 8)Undergoing treatment with fluorocytosine. 9)Hepatitis B virus infection, hepatitis C virus infection. 10)Women who are pregnant or breast-feeding, or Women who may become pregnant and fertile men. 11)Severe mental disorder. 12)Patients judged inappropriate for the study by their physicians.
研究者
相似试验
已完成
2 期
A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic CancerMetastatic/Locally Advanced Pancreatic CancerJPRN-UMIN000008604Wakayama Medical University190
招募中
不适用
A PhaseII Study of Dose Schedule of TS-1 for Metastatic/Advanced Breast CancerMetastatic/Advanced Breast CancerJPRN-UMIN000008879Wakayama Medical University, Department of Thoracic and Cardiovascular Surgery40
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-BEEli Lilly & Company Limited488
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDEUCTR2006-002112-99-FREli Lilly & Company Limited488
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDEUCTR2006-002112-99-SEEli Lilly & Company Limited488